Skip to main content

USDFA

 

 

academics

 

Clinical research courses

  • Accelerate Diagnostics, Inc. announced the submission of a De Novo request for Evaluation of Automatic Class III Designation to the U.S. Food and Drug Administration (FDA) for its Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood culture samples.

    (adsbygoogle = window.adsbygoogle || []).push({});
Subscribe to USDFA